Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

被引:572
作者
Aguayo, A
Kantarjian, H
Manshouri, T
Gidel, C
Estey, E
Thomas, D
Koller, C
Estrov, Z
O'Brien, S
Keating, M
Freireich, E
Albitar, M
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA
关键词
D O I
10.1182/blood.V96.6.2240.h8002240_2240_2245
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiogenesis has been associated with the growth, dissemination, and metastasis of solid tumors. The aims of this study were to evaluate the vascularity and the levels of angiogenic factors in patients with acute and chronic leukemias and myelodysplastic syndromes (MDS), The numbers of blood vessels were measured in 145 bone marrow biopsies and the levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), tumor necrosis growth factor-alpha (TNF-alpha), tumor growth factor-alpha (TGF-alpha), and hepatocyte growth factor (HGF) were determined in 417 plasma samples. Except for chronic lymphocytic leukemia (CLL), vascularity was significantly higher in all leukemias and MDS compared with control bone marrows. The highest number of blood vessels and largest vascular area were found in chronic myeloid leukemia (CML), VEGF, bFGF, and HGF plasma levels were significantly increased in acute myeloid leukemia (AML), CML, CLL, chronic myelomonocytic leukemia (CMML), and MDS, HGF, TNF-alpha, and bFGF but not VEGF were significantly increased in acute lymphoblastic leukemia (ALL), TNF-alpha levels were significantly increased in all diseases except for AML and MDS, No significant increase was found in TGF-alpha in any leukemia or MDS. The highest plasma levels of VEGF were in CML, and the highest plasma levels of bFGF were in CLL. The levels of HGF were highest in CMML. These data suggest that vascularity and angiogenic factors are increased in leukemias and MDS and may play a role in the leukemogenic process. (Blood, 2000;96:2240-2245) (C) 2000 by The American Society of Hematology.
引用
收藏
页码:2240 / 2245
页数:6
相关论文
共 41 条
[1]  
ABBOUD CN, 1995, HEMATOLOGY, P25
[2]  
Aguayo A, 2000, BLOOD, V96, P768
[3]   Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [J].
Aguayo, A ;
Estey, E ;
Kantarjian, H ;
Mansouri, T ;
Gidel, C ;
Keating, M ;
Giles, F ;
Estrov, Z ;
Barlogie, B ;
Albitar, M .
BLOOD, 1999, 94 (11) :3717-3721
[4]   Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology [J].
Banks, RE ;
Forbes, MA ;
Kinsey, SE ;
Stanley, A ;
Ingham, E ;
Walters, C ;
Selby, PJ .
BRITISH JOURNAL OF CANCER, 1998, 77 (06) :956-964
[5]   THE FGF FAMILY OF GROWTH-FACTORS AND ONCOGENES [J].
BASILICO, C ;
MOSCATELLI, D .
ADVANCES IN CANCER RESEARCH, 1992, 59 :115-165
[6]  
Bellamy WT, 1999, CANCER RES, V59, P728
[7]   Role of soluble mediators in angiogenesis [J].
Bussolino, F ;
Albini, A ;
Camussi, G ;
Presta, M ;
Viglietto, G ;
Ziche, M ;
Persico, G .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (14) :2401-2412
[8]   Prognostic value of angiogenesis in gastro-intestinal tumours [J].
Chung, YS ;
Maeda, K ;
Sowa, M .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (14) :2501-2505
[9]  
Cines DB, 1998, BLOOD, V91, P3527
[10]  
DIAZFLORES L, 1994, HISTOL HISTOPATHOL, V9, P807